CBM looks to boost viral vector manufacturing capabilities in cell line deal

By Jane Byrne

- Last updated on GMT

© GettyImages/z_wei
© GettyImages/z_wei

Related tags Center for Breakthrough Medicines cell and gene therapies Cell line

The unprecedented rise in approvals for new cell and gene therapies, and the increasing industry need for cell lines to support the production of therapeutics, has spurred US CDMO, the Center for Breakthrough Medicines (CBM), to act

It has announced a new agreement with Asimov, whereby CBM will license that Boston-based mammalian synthetic biology company’s clonal HEK293 suspension cell line for the production of viral vectors.

The move, said the Philadelphia based CDMO, allows it to offer cell and gene (CGT) therapy developers immediate access to a high-performance clonal GMP-qualified cell line for preclinical and clinical manufacturing,

Manufacturing capabilities supported by this clonal cell line will include both GMP manufacturing (up to 1000L scale) and non-GMP productions (up to 500L), reported the organization.

HEK293 cell lines are the industry standard for producing therapeutic viral vectors, the most widely used vehicle for the delivery of gene therapies, noted the contract development and manufacturing organization (CDMO), which was set up to address bottlenecks in the commercialization of CGTs. 

The company’s process development group evaluated multiple commercially available HEK293 platforms last year, eventually selecting Asimov's one, said Sybil Danby, senior vice president of business development and strategy, CBM.

Cost reduction 

"We continue to make significant investments into our technology platforms to ensure our clients have access to an end-to-end solution that allows them to develop and manufacture at lower costs,”​ added Avi Nandi, chief technical officer, CBM.

Alec Nielsen, Asimov's CEO, said the company’s goal is to enable partners like CBM to improve vector titers, product quality, and bioreactor scalability, in order to increase access to advanced therapies.

The deal comes close on the heels of CBM's launch of its Genesis vector manufacturing platform that includes plasmid manufacturing, process development, high-throughput GMP vector manufacturing suites, integrated testing and analytics, supply chain, and regulatory services co-located at a single site with the goal of accelerating the development and manufacturing timelines of vector-based advanced therapies.

Related news

Show more

Related products

show more

Trends in Biopharmaceutical Raw Material Selection

Trends in Biopharmaceutical Raw Material Selection

Actylis – The Partner of Choice | 31-Jan-2023 | Business Advice

Join us as our in-house experts, along with Cecile Bellamy from Pfizer, discuss current and future trends in biopharmaceutical raw material selection.

eBook: mRNA prospects and scale-up solutions

eBook: mRNA prospects and scale-up solutions

Thermo Fisher Scientific - Biosciences | 01-Jan-2023 | Insight Guide

This mRNA eBook was created by Thermo Fisher Scientific, in collaboration with Genetic Engineering & Biotechnology News (GEN), to provide you with...

Create Better Biologic Treatments with Catalent

Create Better Biologic Treatments with Catalent

Catalent | 06-Dec-2022 | Product Brochure

Your biologics possess a high level of complexities and technical challenges. That’s why development is key to ensuring the successful delivery of your...

Related suppliers

Follow us

Products

View more

Webinars